Pharma Stocks Outlook for the week – 24 to 28.07.2017
Pharma Stocks Outlook for the week – 24 to 28.07.2017
( www.rupeedesk.in )
Stocks of pharmaceutical companies are expected to trade with a positive bias but the mood among
investors may be cautious amid corporate earning announcements for the June quarter. Next week,
Dr Reddy's Laboratories, GlaxoSmithKline Pharmaceuticals and Glenmark Pharmaceuticals will
report their earnings for Apr-Jun. The Hyderabad-based company will report its earnings on
Thursday. Market participants de-stocking of inventories by distribution channels ahead of the rollout of goods and services tax on Jul 1 to limit domestic sales growth of companies for Apr-Jun. In the US
market, market participants will look for commentary of companies' managements on US Food and
Drug Administration approvals for generic drugs and pricing pressure. The US FDA has recently said it plans to speed up approvals for generic drugs to increase competition, which could subsequently lower prices. While faster approvals are seen aiding companies' product launches, the resulting higher competition is seen putting further pressure on prices, according to market participants.
Source : Cogencis Information Services Ltd.
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
Pharma Stocks Outlook for the week – 24 to 28.07.2017
( www.rupeedesk.in )
Stocks of pharmaceutical companies are expected to trade with a positive bias but the mood among
investors may be cautious amid corporate earning announcements for the June quarter. Next week,
Dr Reddy's Laboratories, GlaxoSmithKline Pharmaceuticals and Glenmark Pharmaceuticals will
report their earnings for Apr-Jun. The Hyderabad-based company will report its earnings on
Thursday. Market participants de-stocking of inventories by distribution channels ahead of the rollout of goods and services tax on Jul 1 to limit domestic sales growth of companies for Apr-Jun. In the US
market, market participants will look for commentary of companies' managements on US Food and
Drug Administration approvals for generic drugs and pricing pressure. The US FDA has recently said it plans to speed up approvals for generic drugs to increase competition, which could subsequently lower prices. While faster approvals are seen aiding companies' product launches, the resulting higher competition is seen putting further pressure on prices, according to market participants.
Source : Cogencis Information Services Ltd.
